Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.56 |
| ▸ | RXRB | P28702 | 4/20 | 0.56 |
| ▸ | RXRG | P48443 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236667 | 0.91 | CNR1 (0.62) | RXRARXRBRXRGCNR1CNR2 | |
| SCHEMBL3229159 | 0.87 | CNR1 (0.52) | RXRARXRBRXRGMALT1CNR1 | |
| SCHEMBL3227364 | 0.87 | CNR1 (0.55) | RXRARXRBRXRGCNR1CNR2 | |
| SCHEMBL9519599 | 0.84 | PTGS2 (0.67) | RXRARXRBRXRGMALT1PTGS1 | |
| SCHEMBL3233584 | 0.84 | CCKAR (0.53) | RXRARXRBRXRGCNR1CNR2 | |
| SCHEMBL27775443 | 0.83 | RXRA (0.56) | RXRARXRBRXRGL3MBTL1MALT1 | |
| SCHEMBL9522392 | 0.82 | RXRA (0.81) | RXRARXRBRXRGL3MBTL1MALT1 | |
| SCHEMBL9520300 | 0.76 | ALOX5 (0.79) | RXRARXRBRXRGL3MBTL1MALT1 | |
| Sulfamide SCHEMBL7182772 | 0.76 | PTGS2 (0.76) | L3MBTL1MALT1PTGS1PTGS2 | |
| SCHEMBL3234352 | 0.76 | CNR1 (0.42) | RXRARXRBRXRGL3MBTL1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101663289-B | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RES INST CHEM TECH | 2014-07-23 | — | — | CN | disclosed |
| US-8372844-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-02-12 | — | — | US | disclosed |
| US-20120209001-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-16 | — | — | US | disclosed |
| US-8236806-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-07 | — | — | US | disclosed |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
| CN-101663289-A | Piperazinyl-propyl-pyrazole derivatives and the pharmaceutical composition that comprises them as dopamine d 4 receptor antagonists | KOREA RES INST CHEM TECH | 2010-03-03 | — | — | CN | disclosed |
| WO-2008108517-A2 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209001-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | RXRA 1765/4885RXRB 1311/4885RXRG 1610/4885 |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | RXRA 1765/4885RXRB 1311/4885RXRG 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.